Search research articles
Contact Us
Filters
Showing results (51-60 of 80) with videos related to
Page
of 8
Sort By:
Shock (Augusta, Ga.)
|
June 20, 2007
A role for long chain myosin light chain kinase (MLCK-210) in microvascular hyperpermeability during severe burns
Rashell Reynoso, Rachel M Perrin, Jerome W Breslin, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
March 28, 2025
Optimized 5-HT<sub>2b</sub> inhibitors for neuropsychiatric syndromes with cognitive dysfunction
Saktimayee M Roy, Erica Acquarone, Elentina K Argyrousi, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 25, 2003
An aminopyridazine-based inhibitor of a pro-apoptotic protein kinase attenuates hypoxia-ischemia induced acute brain injury
Anastasia V Velentza, Mark S Wainwright, Magdalena Zasadzki, et al.
Journal of Medicinal Chemistry
|
April 13, 2019
A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction
Saktimayee M Roy, George Minasov, Ottavio Arancio, et al.
Journal of Muscle Research and Cell Motility
|
March 13, 2003
Smooth muscle myosin filament assembly under control of a kinase-related protein (KRP) and caldesmon
Dmitry S Kudryashov, Alexander V Vorotnikov, Tatyana V Dudnakova, et al.
The American Journal of Pathology
|
January 27, 2007
Protection against endotoxic shock as a consequence of reduced nitrosative stress in MLCK210-null mice
Hantamalala Ralay Ranaivo, Nunzia Carusio, Rosemary Wangensteen, et al.
Bioorganic & Medicinal Chemistry
|
March 10, 2009
Analogues of 2-aminopyridine-based selective inhibitors of neuronal nitric oxide synthase with increased bioavailability
Graham R Lawton, Hantamalala Ralay Ranaivo, Laura K Chico, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 10, 2018
p38α MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse
Matthew J Robson, Meagan A Quinlan, Kara Gross Margolis, et al.
Alzheimer'S Research & Therapy
|
December 16, 2016
Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology
Nicole Maphis, Shanya Jiang, Guixiang Xu, et al.
Bioorganic & Medicinal Chemistry
|
November 25, 2010
Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis
Tian Chen, Radhia Benmohamed, Anthony C Arvanites, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 80) with videos related to
Sort By:
Page
of 8
Shock (Augusta, Ga.)
|
June 20, 2007
A role for long chain myosin light chain kinase (MLCK-210) in microvascular hyperpermeability during severe burns
Rashell Reynoso, Rachel M Perrin, Jerome W Breslin, et al.
Alzheimer'S & Dementia (New York, N. Y.)
|
March 28, 2025
Optimized 5-HT<sub>2b</sub> inhibitors for neuropsychiatric syndromes with cognitive dysfunction
Saktimayee M Roy, Erica Acquarone, Elentina K Argyrousi, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 25, 2003
An aminopyridazine-based inhibitor of a pro-apoptotic protein kinase attenuates hypoxia-ischemia induced acute brain injury
Anastasia V Velentza, Mark S Wainwright, Magdalena Zasadzki, et al.
Journal of Medicinal Chemistry
|
April 13, 2019
A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction
Saktimayee M Roy, George Minasov, Ottavio Arancio, et al.
Journal of Muscle Research and Cell Motility
|
March 13, 2003
Smooth muscle myosin filament assembly under control of a kinase-related protein (KRP) and caldesmon
Dmitry S Kudryashov, Alexander V Vorotnikov, Tatyana V Dudnakova, et al.
The American Journal of Pathology
|
January 27, 2007
Protection against endotoxic shock as a consequence of reduced nitrosative stress in MLCK210-null mice
Hantamalala Ralay Ranaivo, Nunzia Carusio, Rosemary Wangensteen, et al.
Bioorganic & Medicinal Chemistry
|
March 10, 2009
Analogues of 2-aminopyridine-based selective inhibitors of neuronal nitric oxide synthase with increased bioavailability
Graham R Lawton, Hantamalala Ralay Ranaivo, Laura K Chico, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 10, 2018
p38α MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse
Matthew J Robson, Meagan A Quinlan, Kara Gross Margolis, et al.
Alzheimer'S Research & Therapy
|
December 16, 2016
Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology
Nicole Maphis, Shanya Jiang, Guixiang Xu, et al.
Bioorganic & Medicinal Chemistry
|
November 25, 2010
Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis
Tian Chen, Radhia Benmohamed, Anthony C Arvanites, et al.
Page
of 8